Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Equity Income: 2024-2025

  • Addex Therapeutics' Equity Income was N/A to -$1.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of -$2.5 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Addex Therapeutics reported Equity Income of -$1.5 million as of Q2 2025, which was down 121.44% from $6.9 million recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Equity Income ranged from a high of $8.1 million in Q4 2024 and a low of -$1.5 million during Q2 2025.
  • Over the past 2 years, Addex Therapeutics' median Equity Income value was $3.0 million (recorded in 2024), while the average stood at $3.1 million.